These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 18245901

  • 21. Activation of eNOS in rat portal hypertensive gastric mucosa is mediated by TNF-alpha via the PI 3-kinase-Akt signaling pathway.
    Kawanaka H, Jones MK, Szabo IL, Baatar D, Pai R, Tsugawa K, Sugimachi K, Sarfeh IJ, Tarnawski AS.
    Hepatology; 2002 Feb; 35(2):393-402. PubMed ID: 11826414
    [Abstract] [Full Text] [Related]

  • 22. High-density lipoprotein administration attenuates liver proinflammatory response, restores liver endothelial nitric oxide synthase activity, and lowers portal pressure in cirrhotic rats.
    Thabut D, Tazi KA, Bonnefont-Rousselot D, Aller M, Farges O, Guimont MC, Tellier Z, Guichard C, Ogier-Denis E, Poynard T, Moreau R, Lebrec D.
    Hepatology; 2007 Dec; 46(6):1893-906. PubMed ID: 17918268
    [Abstract] [Full Text] [Related]

  • 23. Amiloride reduces portal hypertension in rat liver cirrhosis.
    Steib CJ, Hennenberg M, Beitinger F, Hartmann AC, Bystron M, De Toni EN, Gerbes AL.
    Gut; 2010 Jun; 59(6):827-36. PubMed ID: 20551467
    [Abstract] [Full Text] [Related]

  • 24. Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats.
    Abraldes JG, Rodríguez-Vilarrupla A, Graupera M, Zafra C, García-Calderó H, García-Pagán JC, Bosch J.
    J Hepatol; 2007 Jun; 46(6):1040-6. PubMed ID: 17335931
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Salviae miltiorrhizae ameliorates cirrhosis and portal hypertension by inhibiting nitric oxide in cirrhotic rats.
    Wang H, Chen XP, Qiu FZ.
    Hepatobiliary Pancreat Dis Int; 2003 Aug; 2(3):391-6. PubMed ID: 14599946
    [Abstract] [Full Text] [Related]

  • 30. [Renal effects of the chronic inhibition of nitric oxide synthesis in cirrhotic rats with ascites].
    Ortiz MC, Fortepiani LA, Martínez-Salgado C, Eleno N, Atucha NM, López-Novoa JM, García-Estañ J.
    Nefrologia; 2001 Aug; 21(6):556-64. PubMed ID: 11881425
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. In vivo gene transfer of endothelial nitric oxide synthase decreases portal pressure in anaesthetised carbon tetrachloride cirrhotic rats.
    Van de Casteele M, Omasta A, Janssens S, Roskams T, Desmet V, Nevens F, Fevery J.
    Gut; 2002 Sep; 51(3):440-5. PubMed ID: 12171971
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Tyrosine kinase inhibition ameliorates the hyperdynamic state and decreases nitric oxide production in cirrhotic rats with portal hypertension and ascites.
    López-Talavera JC, Levitzki A, Martínez M, Gazit A, Esteban R, Guardia J.
    J Clin Invest; 1997 Aug 01; 100(3):664-70. PubMed ID: 9239414
    [Abstract] [Full Text] [Related]

  • 35. [Effects of spleen on inducing portal hypertension and liver cirrhosis in rats].
    Chen S.
    Zhonghua Yi Xue Za Zhi; 1992 Jun 01; 72(6):338-40, 381-2. PubMed ID: 1332811
    [Abstract] [Full Text] [Related]

  • 36. Evidence that myocardial Na/I symporter gene imaging does not perturb cardiac function.
    Lee KH, Bae JS, Lee SC, Paik JY, Matsui T, Jung KH, Ko BH, Kim BT.
    J Nucl Med; 2006 Nov 01; 47(11):1851-7. PubMed ID: 17079819
    [Abstract] [Full Text] [Related]

  • 37. Role of endothelial nitric oxide synthase in the development of portal hypertension in the carbon tetrachloride-induced liver fibrosis model.
    Theodorakis NG, Wang YN, Wu JM, Maluccio MA, Sitzmann JV, Skill NJ.
    Am J Physiol Gastrointest Liver Physiol; 2009 Oct 01; 297(4):G792-9. PubMed ID: 19628654
    [Abstract] [Full Text] [Related]

  • 38. Neutral endopeptidase (EC 3.4.24.11) in cirrhotic liver: a new target to treat portal hypertension?
    Sansoè G, Aragno M, Mastrocola R, Restivo F, Mengozzi G, Smedile A, Rosina F, Danni O, Parola M, Rizzetto M.
    J Hepatol; 2005 Nov 01; 43(5):791-8. PubMed ID: 16085334
    [Abstract] [Full Text] [Related]

  • 39. Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats.
    Laleman W, Van Landeghem L, Van der Elst I, Zeegers M, Fevery J, Nevens F.
    Gastroenterology; 2007 Feb 01; 132(2):709-19. PubMed ID: 17258737
    [Abstract] [Full Text] [Related]

  • 40. Overexpression of beta-catenin is responsible for the development of portal hypertension during liver cirrhosis.
    Hong JJ, Pan FY, Qian Y, Cheng LC, Zhang HX, Xue B, Li CJ.
    Anat Rec (Hoboken); 2009 Jun 01; 292(6):818-26. PubMed ID: 19462446
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.